Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in the UK
Author(s)
Pavo Marijic, PhD1, Nana Opoku-Ansah, MSc2, Paul Alli, MSc2, Wiliam Hickey, MSc2, Ginita Jutlla, MSc2, Thierry Schaffner, PhD3, Elise Kuylen, PhD4, Gaurav Mathur, MSc5, Nicola Clarke, MSc6, Andrew Easton, MSc6, Thatiana de Jesus Pereira Pinto, PhD4, Zeki Kocaata, PhD4.
1GSK, Munich, Germany, 2GSK, London, United Kingdom, 3GSK, London, Switzerland, 4GSK, Wavre, Belgium, 5GSK, Philadelphia, PA, USA, 6Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom.
1GSK, Munich, Germany, 2GSK, London, United Kingdom, 3GSK, London, Switzerland, 4GSK, Wavre, Belgium, 5GSK, Philadelphia, PA, USA, 6Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom.
OBJECTIVES: There is a “second peak” of invasive meningococcal disease (IMD) - particularly serogroup B IMD (MenB) - among adolescents and young adults, putting them at risk of severe complications and posing a significant economic burden. This systematic literature review assessed the epidemiology, disease burden, and economic burden of IMD in the UK, focusing on adolescents and young adults (10-24-year-olds).
METHODS: Searches in March 2025 included peer-reviewed literature from MEDLINE and Embase (past 10 years), conference proceedings (past 3 years), and relevant websites and governmental/non-governmental organisations. Outcomes included epidemiological and disease burden and acute and long-term healthcare resource utilisation and costs.
RESULTS: Data were extracted from 34 sources. From surveillance reports, peak IMD incidences across multiple years were among <5-year-olds, with a second peak among 15-24-year-olds. IMD incidences decreased over time and most cases were MenB in all years. The highest MenB incidence rate in 2023 was 6.1 per 100,000 <1-year-olds with a second peak of 2.2 per 100,000 15-19-year-olds. Sepsis, meningitis, and physical/neurological sequelae were reported in 0-54%, 0-83%, and 0-33%/0-61% of IMD cases, respectively (overall populations). Mean length of hospitalisation was 7 days (overall populations) and intensive care unit admissions were reported for 33-38% of 5-24-year-olds. Estimated acute IMD costs (IMD or MenB) were approximately £9,000 regardless of age. Other estimated costs included acute productivity loss (£382 [child case] or £2,286 [adult case]), long-term sequelae (first-year costs of £134-52,166) and formal long-term care (£9,136/year) (overall populations).
CONCLUSIONS: Although routine MenB and MenACWY vaccinations have reduced IMD incidence, IMD is associated with severe complications and high costs. MenB remains dominant, with incidence peaks in those aged <5 and 15-24 years. These findings underscore the importance of MenB prevention and can help to inform health strategies and economic planning for better disease prevention and management.
METHODS: Searches in March 2025 included peer-reviewed literature from MEDLINE and Embase (past 10 years), conference proceedings (past 3 years), and relevant websites and governmental/non-governmental organisations. Outcomes included epidemiological and disease burden and acute and long-term healthcare resource utilisation and costs.
RESULTS: Data were extracted from 34 sources. From surveillance reports, peak IMD incidences across multiple years were among <5-year-olds, with a second peak among 15-24-year-olds. IMD incidences decreased over time and most cases were MenB in all years. The highest MenB incidence rate in 2023 was 6.1 per 100,000 <1-year-olds with a second peak of 2.2 per 100,000 15-19-year-olds. Sepsis, meningitis, and physical/neurological sequelae were reported in 0-54%, 0-83%, and 0-33%/0-61% of IMD cases, respectively (overall populations). Mean length of hospitalisation was 7 days (overall populations) and intensive care unit admissions were reported for 33-38% of 5-24-year-olds. Estimated acute IMD costs (IMD or MenB) were approximately £9,000 regardless of age. Other estimated costs included acute productivity loss (£382 [child case] or £2,286 [adult case]), long-term sequelae (first-year costs of £134-52,166) and formal long-term care (£9,136/year) (overall populations).
CONCLUSIONS: Although routine MenB and MenACWY vaccinations have reduced IMD incidence, IMD is associated with severe complications and high costs. MenB remains dominant, with incidence peaks in those aged <5 and 15-24 years. These findings underscore the importance of MenB prevention and can help to inform health strategies and economic planning for better disease prevention and management.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
SA89
Topic
Study Approaches
Disease
Rare & Orphan Diseases, Vaccines